Login to Your Account

Antisoma Picks Up $65M by Selling Fludarabine

By Nuala Moran

Wednesday, May 13, 2009
LONDON - Antisoma plc has sold its oral fludarabine product to Sanofi-Aventis SA for an immediate cash payment of £39.4 million (US$60 million) and further payments totaling $5 million, in a deal that will extend its cash resources from mid-2010 to 2011, providing sufficient funding to see the two lead therapies through to the end of Phase III. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription